Diligence memo · auto-generated · as of July 2, 2026

Eye C Better Corp.

Eye C Better Corp. looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Eye C Better Corp. operates in Other Health Care, based in INDIO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Eye C Better Corp. has raised $955K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $855K on 2021-09-14.

Most recent recorded round closed around 2021-09-14.

Valuation (modeled)modeled

Provath models Eye C Better Corp. at approximately $14M (range $536K–$114M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.79× the median modeled value of Pre-Seed Other Health Care companies in 2019–2021 (295 peers) — value vs value, same stage and era. Issuer reports no revenue, yet is modeled well above niche peers.

Financing rhythm & timingmixed

Historic cadence: a new round about every 0 months.

Last raise 4.8 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 2.9× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 32% of Other Health Care peers (5377 compared).

Modeled value ranks above 41% of those peers.

Closest niche peers: Aetas Co LLC, Hauppauge SC Holdings, LLC, Gateway IV Lithotripsy, LLC, Endoscopy Center of West Central Ohio, LLC, Dalent LLC.

Peoplefiled

2 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.